-transparent.png){kind=logo}
Our retrospective study for ultrasonic nebulised pentamidine in 13 patients shows that 7 of 8 patients with Pneumocystis carinii pneumonia (PCP), proven by biopsy examination, were cured (recovery rate, 88%). Two of these 8 patients were mainly treated by nebulised pentamidine and the other 5 patients were administered parenteral pentamidine before the nebulised pentamidine therapy and the final 1 patient died on day 9 without clinical improvement with nebulised pentamidine as well as conventional therapy (trimethoprim-sulphamethoxazole, parenteral pentamidine). No relapse occurred in the 7 cured patients. The inhalation increased the cough in 4 of 13 cases and caused vomiting in 1 patient. Two patients discontinued the nebulisation because of the side-effect. No extra-pulmonary side-effects of nebulised pentamidine were seen. These results show that an efficacy of nebulised pentamidine is at least equal to conventional therapy with fewer side-effects and that only patients with mild PCP without severe hypoxaemia are eligible for the inhalation therapy.
K Tanabe, and
H Goto, and
K Shimada
May 1988,
Lancet (London, England),
K Tanabe, and
H Goto, and
K Shimada
January 1985,
The Medical letter on drugs and therapeutics,
K Tanabe, and
H Goto, and
K Shimada
July 1989,
Thorax,
K Tanabe, and
H Goto, and
K Shimada
October 1989,
Thorax,
K Tanabe, and
H Goto, and
K Shimada
April 1990,
Clinical pediatrics,
K Tanabe, and
H Goto, and
K Shimada
November 1988,
Drug intelligence & clinical pharmacy,
K Tanabe, and
H Goto, and
K Shimada
October 1989,
Chest,
K Tanabe, and
H Goto, and
K Shimada
November 1966,
Pediatrics,
K Tanabe, and
H Goto, and
K Shimada
July 1990,
The Western journal of medicine,
K Tanabe, and
H Goto, and
K Shimada
March 1990,
Connecticut medicine,
